Archief

89ZR-CX-072-PET scan studie

5 mei 2021

ACT

12 april 2021

Optimal Timing of a tailored Physical Activity program during chemotherapeutic Cancer Treatment to reduce Long-term Cardiovascular Morbidity METc nr: 2012/260 Onderzoekscode: ON76 ClinicalTrials.gov registratie: NCT01642680 Samenvatting Het aantal…

ACT

6 mei 2021

Optimal Timing of a tailored Physical Activity program during chemotherapeutic Cancer Treatment to reduce Long-term Cardiovascular Morbidity METc nr: 2012/260 Onderzoekscode: ON76 ClinicalTrials.gov registratie: NCT01642680 Samenvatting Het aantal…

ACT NY ESO synoviosarcoom

12 april 2021

Samenvatting In het AVL is de TCR studie voor NY ESO pos synoviosarcoom patiënten open. Gemetastaseerde synoviosarcoom patiënten voor eerste lijns/tweedelijns behandeling kunnen geïncludeerd worden. Er is in…

AIPAC

Active Immunotherapy PAClitaxel: A multicentre, Phase IIb, randomized, double blind, placebo-controlled study in hormone receptor-positive metastatic breast carcinoma patients receiving IMP321 (LAG-31g fusion protein) or placebo as adjunctive…

ALT-GIST EORTC 1321

ALT-GIST: A randomised phase II trial of imatinib alternating with regorafenib compared to imatinib alone for the first line treatment of advanced gastrointestinal stromal tumour (GIST). EORTC study…

AMG 479

A phase 3, multicenter, randomized, double-blind, placebo controlled, trial of AMG 479 or placebo in combination with Gemcitabine as first-line therapy for metastatic adenocarcinoma of the pancreas.

ANZadapt studie

8 juni 2023

ANZadapt studie Phase II randomised controlled trial of patient-specific adaptive versus continuous Abiraterone or eNZalutamide in metastatic castration-resistant prostate cancer: the ANZadapt study Samenvatting De ANZadapt studie is…

ASCENT-03

4 april 2023

A Randomized, Open-label, Phase 3 Study of Sacituzumab Govitecan Versus Treatment of Physician’s Choice in Patients With Previously Untreated, Locally Advanced, Inoperable or Metastatic Triple-Negative Breast Cancer Whose…

ASCENT-04

A Randomized, Open-label, Phase 3 Study of Sacituzumab Govitecan and Pembrolizumab Versus Treatment of Physician’s Choice and Pembrolizumab in Patients With Previously Untreated, Locally Advanced Inoperable or Metastatic…

Ave-short-trial

11 mei 2022

Een nationaal, multicenter, niet-geblindeerde doelmatigheids studie waarbij zes maanden avelumab onderhoudsbehandeling wordt gegeven aan patienten met een lokaal gevorderd of gemetastaseerde urotheelcarcinoom zonder ziekteprogressie na minimaal 4 kuren…

BLU-667

12 april 2021

A Phase 1 Study of the Highly-selective RET Inhibitor, BLU-667, in Patients with Thyroid Cancer, Non-Small Cell Lung Cancer (NSCLC) and Other Advanced Solid Tumors. Protocolnummer: BLU-667-1101 Eudract…

BLU-667 studie (named-patient programma)

Zie BEACON: NET – medullair schildkliercarcinoom – palliatief – BLU-667 studie (named-patient programma)

Breast Optical Imaging

Validation of Uptake of a VEGF-targeted Optical Fluorescent Imaging Tracer in Surgical Specimens of Breast Cancer and Application of Pre- and Intra-operative Human Molecular Fluorescence Imaging Techniques. A…

CA017-078

A Phase 3, Randomized, Study of Neoadjuvant Chemotherapy alone versus Neoadjuvant Chemotherapy plus Nivolumab or Nivolumab and BMS-986205, Followed by Continued Post- Surgery Therapy with Nivolumab or Nivolumab…